1. Introduction
===============

Ovarian cancer is a frequent malignant tumor in the female reproductive system and is often diagnosed late due to the lack of effective early diagnostic methods, which leads to the tumor\'s higher mortality rates.^\[[@R1]\]^ Due to the lack of early specific clinical symptoms, the diagnosis, treatment, and prognosis of the disease are seriously affected. Therefore, it is clinically essential to find sensitive and specific tumor markers to evaluate the degree of malignancy and improve the prognosis and survival rate of ovarian cancer patients.

B7-H4, also known as B7s1 or B7x, is a newly discovered member of its family that is expressed in antigen-presenting cells.^\[[@R2]\]^ Studies have found that B7-H4 is expressed in many tumor tissues, including ovarian, breast, prostate, and esophageal cancers, and is associated with tumor occurrence, development, and prognosis.^\[[@R3]--[@R5]\]^ B7-H4 was overexpressed in ovarian cancer tissue, while it was either not expressed or less expressed in normal ovarian tissue, indicating it is a potential tumor marker for ovarian cancer.^\[[@R6],[@R7]\]^ It is reasonable to speculate that B7-H4 expression may be closely related to the pathogenesis of ovarian cancer. However, the role and the prognostic value of B7-H4 expression in ovarian cancer remain unclear. Therefore, we conducted a systematic review to explore the correlation between B7-H4 expression and ovarian cancer, in addition to determining its clinicopathologic characteristics and prognostic value.

2. Methods
==========

2.1. Search strategy
--------------------

This meta-analysis was conducted in accordance with the guidelines of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. A comprehensive search of PubMed, MEDLINE, Cochrane Library, and the China National Knowledge Infrastructure databases was performed through September 2017. The following search strategy was used: ("B7-H4" OR "*V-set domain containing T-cell activation inhibitor 1*" OR "B7s1" OR "B7x") and ("ovarian cancer" OR "ovarian tumor" OR "ovarian neoplasm" OR "cancer of the ovarian"). Subsequently, the eligible literature was included for further screening.

2.2. Study selection
--------------------

Two researchers independently screened the eligible literature. The inclusion criteria were that the authors measured B7-H4 expression in tumor tissue and reported the clinicopathologic characteristics and survival. Exclusion criteria were the use of animals, reviews, comments, or irrelevant articles, and data that comprised continuous variables or that were incomplete.

2.3. Data extraction
--------------------

The following items were collected from the included studies: the first author\'s name, publication year, country in which the study was performed, age, number of patients, cutoff value, detection method for B7-H4 expression, number of B7-H4 positives, recruitment period, and outcome. The hazard ratio (HR) was extracted from survival curve plots when data could not be obtained directly. All authors agreed to the final determinants of the literature to be considered.

2.4. Study quality assessment
-----------------------------

According to the guidelines of the Newcastle--Ottawa scale (NOS),^\[[@R8]\]^ 2 independent authors (SLL and JJW) evaluated the quality of the included retrospective studies. The included studies were classified into 2 levels: low quality (0--6) and high quality (7--9).^\[[@R9]\]^ A third investigator (YY) adjudicated when disagreements on the enrolled studies occurred.

2.5. Statistical analysis
-------------------------

The statistical software, Stata version 14.0 (Stata Corp LP, College Station, TX), was used to perform statistical analyses. The B7-H4 cutoff values classified cancer patients into high and low expression groups. Statistical heterogeneity across the eligible studies was inspected by processing the Cochran *Q*-statistic test (*P* ≤ .05 were treated as statistically significant) and calculating the *I*^*2*^ statistic.^\[[@R10],[@R11]\]^*I*^2^ values of 25%, 50%, and 75% represented low, medium, and high heterogeneity, respectively.^\[[@R12]\]^ A random-effects model was used when the *I*^*2*^ was \>50% and *P*-value was \<.05; otherwise, the fixed effects model was used. Sensitivity analysis was conducted to validate the outcome credibility by deleting individual studies in the meta-analysis. A funnel plot was used to identify evidence of publication bias. Egger linear regression test was used to evaluate funnel plot symmetry. To calculate the effect size of the clinicopathologic characteristics, the summary odds ratios (ORs) with their 95% confidence intervals (CIs) were used for International Federation of Gynaecology and Obstetricsstages (FIGO), pathologic grade, tumor metastasis, and histologic type of B7-H4 expression. The PFS value from each study was determined by combining the HR and its corresponding 95% CI. A *P*-value of .05 was regarded as statistically significant, and all tests were 2-sided.

3. Results
==========

3.1. Literature search
----------------------

The study search details are presented in a flow diagram (Fig. [1](#F1){ref-type="fig"}). In total, 156 relevant studies were identified from a search of the above databases using the search strategy as described earlier. After carefully reading each article, 104 studies were excluded because they were duplicates, letters, reviews, nonhuman studies, or contained limited data. Upon further review, 42 additional studies were excluded because they were irrelevant to B7-H4 or ovarian cancer. Finally, a total of 10 publications were enrolled for the present meta-analysis. The selection process is shown in Figure [1](#F1){ref-type="fig"}.

![Flow chart showing the study selection procedure.](medi-97-e11821-g001){#F1}

3.2. Study characteristics
--------------------------

Characteristics of the selected studies are listed in Table [1](#T1){ref-type="table"}. The 10 studies were published between 2007 and 2017, including 2 American studies^\[[@R7],[@R13]\]^ and 8 Asian studies.^\[[@R14]--[@R21]\]^ A median NOS score of 7 was identified as indicating reliable quality. We explored the correlation between B7-H4 expression and ovarian cancer (7 studies). Furthermore, we compared the positive expression of B7-H4 between the following pairs: FIGO I+II versus III+IV groups (10 studies), high- and medium-differentiation versus low-differentiation groups (9 studies), metastasis versus nonmetastasis (7 studies), serous versus mucinous (9 studies), and the relationship between positive B7-H4 expression and patient PFS (3 studies).

###### 

Characteristics of the eligible studies in the meta-analysis.

![](medi-97-e11821-g002)

3.3. Meta-analysis
------------------

### 3.3.1. Correlation between B7-H4 expression and ovarian cancer

We compared the rate of positive B7-H4 expression in the 7 included studies. The pooled OR was 4.20 (95% CI: 2.85--6.18, *Z* = 6.91, *P* \< .05), and heterogeneity between the studies was low (*I*^2^ = 8.2%, *P* = .366) (Fig. [2](#F2){ref-type="fig"}).

![Forest plots for the relationship between B7-H4 expression and prostate cancer. CI = confidence interval, OR = odds ratio.](medi-97-e11821-g003){#F2}

### 3.3.2. Association between positive B7-H4 expression and clinicopathologic characteristics

The positive B7-H4 expression rates between the FIGO I+II and FIGO III+IV stages were compared in 10 studies. The pooled OR was 0.81 (95% CI: 0.64--1.03, *Z* = 1.70, *P* = .09) with low significant heterogeneity (*I*^2^ = 18.1%, *P* = .28). In addition, the positive expression of B7-H4 between the groups with tumor metastasis and nonmetastasis was compared in 7 studies. The pooled OR was 1.25 (95% CI: 0.90--1.74, *Z* = 1.34, *P* = .18), with low significant heterogeneity (*I*^2^ = 12.1%, *P* = .34). Furthermore, B7-H4 was more highly expressed in ovarian cancer patients with high differentiation grade in 3 studies (OR: 0.91, 95% CI: 0.72--1.16, *Z* = 0.76, *P* = .45), and medium significant heterogeneity was detected (*I*^2^ = 70.5%, *P* = .001). The results also suggest that there was no statistically significant difference between serous and mucinous ovarian cancer patients in 9 studies (OR: 1.17, 95% CI: 0.85--1.60, *Z* = 0.96, *P* = .34) and no evidence of heterogeneity (*I*^2^ = 0%, *P* = .68). We conclude that positive B7-H4 expression was not associated with the clinicopathologic characteristics of ovarian cancer (Fig. [3](#F3){ref-type="fig"}).

![Forest plots for the relationship between B7-H4 expression and clinicopathologic characteristics of ovarian cancer. CI = confidence interval, OR = odds ratio, FIGO = International Federation of Gynaecology and Obstetricsstages.](medi-97-e11821-g004){#F3}

### 3.3.3. Meta-analysis of B7-H4 expression and PFS

Three studies provided data on the association between B7-H4 expression and PFS. The analysis results suggested that B7-H4 expression was associated with PFS (HR: 1.30, 95% CI: 1.17--1.45, *Z* = 4.79, *P* \< .05) with medium significant heterogeneity (*I*^*2*^ = 64.3%, *P* = .06) (Fig. [4](#F4){ref-type="fig"}).

![Forest plot of the association between B7-H4 overexpression and ovarian cancer PFS. CI = confidence interval, HR = hazard ratio.](medi-97-e11821-g005){#F4}

### 3.3.4. Publication bias and sensitivity analysis

Funnel plots and Egger test were used to evaluate publication bias. The funnel plots of the studies were symmetrical, and Egger test showed no publication bias (Fig. [5](#F5){ref-type="fig"}). The overall significance did not change when any single study was omitted. Sensitivity analysis showed that the data were relatively stable and reproducible (Fig. [6](#F6){ref-type="fig"}).

![Funnel plot analysis of publication bias. FIGO = International Federation of Gynaecology and Obstetricsstages, HR = hazard ratio, OR = odds ratio, PFS = progression-free survival.](medi-97-e11821-g006){#F5}

![Results of the sensitivity analysis. CI = confidence interval, FIGO = International Federation of Gynaecology and Obstetricsstages, PFS = progression-free survival.](medi-97-e11821-g007){#F6}

4. Discussion
=============

Ovarian cancer is a malignant tumor of the female reproductive system with high mortality.^\[[@R22]\]^ Because the ovarian tissue is located deep in the pelvic cavity, early symptoms are not obvious, and the lack of effective detection methods means that most patients are in the middle and late stages when seeking medical treatment. Thus, the 5-year survival rate is only 20% to 30%.^\[[@R23]\]^ Therefore, the search for a specific and sensitive tumor molecular marker has important clinical significance for guiding treatment and improving the prognosis of ovarian cancer patients.

As determined bioinformatically in 2003, B7-H4 negatively regulates T-cell-mediated immune response genes.^\[[@R24]\]^ It inhibits T-cell cytokine proliferation and cell cycle processes to negatively regulate T-cell immune responses; therefore, it is highly expressed in various tumor tissues and plays an important role in tumor occurrence and development.^\[[@R25],[@R26]\]^ Enhanced B7-H4 expression results in tumor immune escape and is associated with ovarian cancer occurrence, thus making it a potential new biomarker for early diagnosis and treatment of ovarian cancer.^\[[@R27]\]^ However, the relationship between B7-H4 overexpression and ovarian cancer patient prognosis remains unclear. Additionally, no relevant meta-analysis has yet reported the relationship between B7-H4 expression and clinicopathologic characteristics of ovarian cancer patients. An expanded study is needed to conclude whether B7-H4 expression is a predictive factor. In this meta-analysis, we explored the relationship between B7-H4 expression and the clinicopathologic characteristics and prognosis of ovarian cancer patients.

First, we included 376 patients and 180 controls from 7 studies to analyze the correlation between B7-H4 expression and ovarian cancer. The pooled OR was 4.20 (95% CI: 2.85--6.18, *Z* = 6.91, *P* \< .05), indicating that B7-H4 expression was associated with PCa, and heterogeneity was low between studies (*I*^2^ = 8.2%, *P* = .366). Next, we evaluated clinicopathologic characteristics of ovarian cancer, such as pretreatment clinical FIGO stages, pathologic grade, tumor metastasis, and histologic type, which have important clinical value. The effect size for clinicopathologic characteristics was calculated, and we found no association between clinicopathologic characteristics of ovarian cancer and positive expression of B7-H4. Finally, we conducted a review to analyze the relationship between B7-H4 expression and ovarian cancer patient prognosis. In our analysis, the pooled HR of B7-H4 on PFS was 1.30 (95% CI: 1.17--1.45, *P* \< .05), which verified that B7-H4 indicates a worse outcome for ovarian cancer patients.

Simon found that the tumor malignancy degree increased as B7 levels increased.^\[[@R28]\]^ However, Zhang et al reported that the expression of B7 in ovarian cancer was unrelated to clinicopathologic factors such as patient age and lymph node metastasis.^\[[@R15]\]^ Based on the results of our meta-analysis, we assume that B7-H4 expression is a biomarker for ovarian cancer, but it is uncorrelated with clinicopathologic characteristics. The previous meta-analysis investigated whether high B7-H4 expression influenced the prognosis of solid tumor patients.^\[[@R29]\]^ In our study, we found that high expression of B7-H4 was an independent prognostic indicator of poor survival. However, certain limitations to our study should be considered. First, continuous variable data were not included. Second, most of the included studies were conducted in the Asian population. Third, HRs were extracted from survival curves when directly reported HR values were lacking, which may have introduced an element of decreased reliability. In our future research, we plan to design a prospective randomized, controlled trial to explore differences and avoid selection bias.

5. Conclusion
=============

The results of this meta-analysis suggest that B7-H4 expression is related to ovarian cancer and poor prognosis, but unrelated to the clinicopathologic characteristics of ovarian cancer patients.
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